NQ Mobile Raises First Quarter Guidance; NPS Pharmaceuticals Could be bought out by Shire


Investment Opinion

Share Tweet

NQ Mobile Raises First Quarter Guidance; NPS Pharmaceuticals Could be bought out by Shire

NQ Mobile Inc. (NYSE: NQ) shares closed up nearly 12% on about 19.8 million shares traded. The stock was one of the biggest gainers on the NYSE this past Friday. The stock soared as much as 29% during intra-day trading after the company raised its first-quarter guidance. NQ Mobile also announced the sale of a minority stake in its wholly owned subsidiary, FL Mobile.

NQ Mobile Inc. provides mobile Internet services in the areas of mobile security, privacy, productivity, personalized cloud, and family protection. It operates through two segments, Consumer and Enterprise. The company offers NQ Mobile Security, a mobile security product that protects users’ mobile voice and data from malicious software, data theft, and privacy intrusion; and mobile security services, such as mobile malware scanning, Internet firewall, account and communication safety, anti-theft, performance optimization, hostile software rating, and reporting

Get more information on NQ Mobile Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/NQ

TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) shares closed up 13.41% on about 15.3 million shares. The stock was a big gainer on the NASDAQ this past Friday. The stock moved as much as 26% during intra-day trading after rumors revealed that the company may be bought out. According to a report from FT Alphaville, which cited familiar sources, Shire has held internal talks and has been working with its advisors to possible arrange an all-cash offer for NPS Pharmaceuticals of around $40 per share.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.

Get more information on NPS Pharmaceuticals, Inc. and free access to the in depth equity report at” www.TrendingWallStreet.com/stockquote/NPSP


Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.